Based on the results of this study and these findings, we hypothesized that TP53 mutations in cancer types of cluster A1 increase tumor malignancy and shorten the prognosis but they increase sensitivity to anticancer drugs compared to cancer types of cluster A2. The gene discussed is TP53; the disease is neoplasm.